Durvalumab: beside a new treatment under test

248 studies: a new drug, cell therapy or vaccine is what the study tests. Page 3 of 3. Open to participants first (57), then studies with results posted, then the rest; newest registration first within each.

• Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast CancerTerminatedNCT03430466Phase 2Report a problem
• Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCCCompletedNCT03426657Phase 2Report a problem
• AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung CancerCompletedNCT03421353Phase 1Report a problem
• Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung CancerWithdrawnNCT03419559Phase 2Report a problem
• Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid MalignanciesCompletedNCT03394144Phase 1Report a problem
• Prostate Cancer Biomarker Enrichment and Treatment SelectionActive, not recruitingNCT03385655Phase 2Report a problem
• IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell CarcinomaCompletedNCT03381183Phase 1Report a problem
• Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal CancerStatus unknownNCT03377400Phase 2Report a problem
• Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)WithdrawnNCT03319316Phase 2Report a problem
• Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue SarcomaCompletedNCT03317457Phase 2Report a problem
• Study of Durvalumab and Guadecitabine in Advanced Kidney CancerActive, not recruitingNCT03308396Phase 1/2Report a problem
• Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]CompletedNCT03292250Phase 2Report a problem
• Immunotherapy and SBRT for Metastatic Head and Neck CarcinomasCompletedNCT03283605Phase 1/2Report a problem
• Durvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerTerminatedNCT03277482Phase 1Report a problem
• Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint InhibitionTerminatedNCT03275597Phase 1Report a problem
• Trial in Patients With Relapsed Ovarian CancerCompletedNCT03267589Phase 2Report a problem
• Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder CancerActive, not recruitingNCT03257761Phase 1Report a problem
• A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid TumorsCompletedNCT03238027Phase 1Report a problem
• Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for CisplatinTerminatedNCT03234153Phase 2Report a problem
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2Report a problem
• A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic CancerCompletedNCT03212469Phase 1/2Report a problem
• Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRCCompletedNCT03202758Phase 1/2Report a problem
• Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell TumorsActive, not recruitingNCT03158064Phase 2Report a problem
• Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder CancerWithdrawnNCT03150836Phase 2Report a problem
• Synergism of Immunomodulation and Tumor AblationCompletedNCT03101475Phase 2Report a problem
• MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.CompletedNCT03089645Phase 1Report a problem
• Biomarker-based Study in R/M SCCHNActive, not recruitingNCT03088059Phase 2Report a problem
• SGI-110 Plus Durvalumab/Tremelimumab in SCLCCompletedNCT03085849Phase 1Report a problem
• Pulmonary sarcomatoid_MEDI4736+TremeCompletedNCT03022500Phase 2Report a problem
• Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the LiverCompletedNCT03005002Phase 1Report a problem
• MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT03004105Phase 2Report a problem
• Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral CavityWithdrawnNCT02993991Phase 1Report a problem
• Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid TumorsCompletedNCT02900157Phase 1Report a problem
• Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis FungoidesTerminatedNCT02890368Phase 1Report a problem
• Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast CancerActive, not recruitingNCT02826434Phase 1Report a problem
• A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid MalignanciesCompletedNCT02740985Phase 1Report a problem
• A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic CancerCompletedNCT02734160Phase 1Report a problem
• Pilot Study of Durvalumab and Vigil in Advanced Women's CancersCompletedNCT02725489Phase 2Report a problem
• A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid TumorsCompletedNCT02705482Phase 1Report a problem
• Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung CancerWithdrawnNCT02673814Phase 2Report a problem
• Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid TumoursCompletedNCT02617277Phase 1Report a problem
• A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursCompletedNCT02586987Phase 1Report a problem
• A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid TumorsTerminatedNCT02556463Phase 1Report a problem
• Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingNCT02546661Phase 1Report a problem
• MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.CompletedNCT02503774Phase 1Report a problem
• In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®CompletedNCT02423863Phase 2Report a problem
• Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid TumorsCompletedNCT02301130Phase 1Report a problem
• A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid TumorsCompletedNCT02221960Phase 1Report a problem

← Durvalumab